United States Patent 8,840,916: Polymer Scope, Claim Construction, Patent Landscape, and Generic-Entry Risk

US 8,840,916 is a composition-of-matter patent directed to hydroxyl-terminated biodegradable polymers containing a poly(lactide-co-glycolide), or PLG, segment. The claims do not cover a specific small-molecule drug, biologic, dosage strength, or finished pharmaceutical product. They cover a defined polymer class that may be used as a drug-delivery excipient, depot matrix, microsphere material, implant component, or controlled-release carrier.

The commercial scope depends on whether a competing product uses the claimed polymer architecture, satisfies the molecular-weight and physical-property limitations, and falls within the lactide/glycolide and linker ranges.

What does US Patent 8,840,916 claim?

Claim 1 is the only independent claim in the supplied claim set. It requires every limitation below:

Claim 1 limitation	Scope
Polymer of Formula I/II	The polymer must conform to the structural formula shown in the patent
PLG segment	L/G must represent a poly(lactide-co-glycolide) segment
Terminal hydroxyl groups	The distal ends are represented by hydrogen atoms borne by terminal hydroxyl groups
Alkylene diradical	Ra connects the relevant polymer segments through an alkylene linker
Rb and Rc	Each is hydrogen or methyl
Water and body-fluid insolubility	The polymer must be substantially insoluble in water and body fluid
Acid-group limitation	The polymer must have substantially no titratable carboxylic acid groups
Molecular weight	Weight-average molecular weight is about 10 kDa to about 50 kDa
Physical state	Neat polymer is solid at ambient temperature

A product must satisfy the structural, chemical, molecular-weight, and physical-property limitations together. A PLGA polymer that satisfies only the lactide/glycolide ratio is outside claim 1 unless it also meets the linker, terminal-group, acid-functionality, molecular-weight, solubility, and solid-state requirements.

The claim language indicates a polymer with PLG-derived biodegradable domains and a non-PLG alkylene-linked structure represented by Ra. Because the formula image is not reproduced in the supplied text, the exact connectivity of the Formula I/II embodiments cannot be reconstructed from the text alone. The scope analysis therefore rests on the express limitations and not on an inferred structural drawing.

What polymer characteristics are protected by US 8,840,916?

The patent protects a narrow subset of PLG-based polymers rather than conventional PLGA broadly.

PLG composition range

Claim 2 covers a lactide/glycolide ratio of approximately 45/55 to 99/1. Claim 3 narrows that range to approximately 70/30 to 90/10.

The dependent range in claim 3 is commercially significant because a polymer containing approximately 70% to 90% lactide may have different crystallinity, degradation rate, hydrophobicity, glass-transition behavior, and drug-release characteristics from a glycolide-rich polymer.

A polymer with a lactide/glycolide ratio below approximately 45/55 or above approximately 99/1 may avoid claims 2 and 3, although it could still fall within claim 1 if the broader formula and other claim 1 limitations are satisfied.

Molecular-weight range

Claim 1 requires approximately 10 kDa to 50 kDa. Claim 4 recites approximately 8 kDa to 100 kDa, but it depends on claim 1. As a result, claim 4 cannot ordinarily expand the scope beyond claim 1's inherited limitations. The practical operative range for claims 4 through 12 remains subject to the claim 1 requirement of approximately 10 kDa to 50 kDa.

The narrower ranges are:

Claim	Weight-average molecular weight
1	About 10-50 kDa
4	About 8-100 kDa, subject to claim 1
5	About 10-50 kDa
6	About 15-45 kDa

This creates a potential claim-drafting issue. Claim 4's broader numerical range does not necessarily create a broader enforceable scope because the dependent claim incorporates all limitations of claim 1.

Linker limitation

Claim 7 requires Ra to be a linear, unsubstituted carbon chain. Claim 8 narrows Ra to a six-carbon chain. A six-carbon linear unsubstituted alkylene linker is therefore the most specifically identified linker in the supplied claims.

A polymer using a branched, substituted, heteroatom-containing, unsaturated, or cyclic linker may avoid claims 7 and 8. It may remain exposed to claim 1 if the broader definition of Ra in the patent includes that linker.

Polydispersity

Claims 9 and 10 require:

Claim	Polydispersity
9	About 1.2-2.0
10	About 1.4-1.7

Polydispersity is a product-characterization limitation. Enforcement would require agreement on the analytical method, calibration standard, solvent, sample preparation, and whether the result is weight-average molecular weight divided by number-average molecular weight.

Inherent viscosity

Claims 11 and 12 require:

Claim	Inherent viscosity
11	About 0.20-0.60 dL/g
12	About 0.25-0.40 dL/g

Inherent viscosity is also method-sensitive. A competitor could challenge infringement by showing that testing conditions materially change the reported value. The patent's specification and prosecution history would control the relevant solvent, concentration, temperature, and calculation method.

How broad is independent claim 1?

Claim 1 has meaningful breadth because it does not require:

A particular active pharmaceutical ingredient
A particular drug-loading percentage
A microsphere, implant, nanoparticle, or injectable dosage form
A specific route of administration
A specific degradation period
A therapeutic indication
A specific manufacturing process
A particular lactide stereochemical composition, unless imposed elsewhere in the specification or prosecution history

The claim is also constrained by functional and physical limitations. A polymer must be substantially insoluble in water and body fluid, have substantially no titratable carboxylic acid groups, fall within the stated molecular-weight range, and be solid in neat form at ambient temperature.

Those limitations may distinguish the claimed polymers from:

Acid-terminated PLGA
Low-molecular-weight PLGA oligomers
Water-soluble polymer conjugates
Liquid polymer formulations
Polymers with substantial free carboxylic-acid functionality
Polymers outside the molecular-weight range

The principal infringement question is whether the competing material is structurally and analytically within the claimed genus, not whether it is used for the same therapeutic purpose.

What formulations are protected by US 8,840,916?

The supplied claims protect the polymer itself, not a formulation as such. A formulation may create indirect infringement exposure if it contains a polymer meeting claim 1 or a dependent claim.

Potentially relevant products include:

Injectable depot formulations
Biodegradable microspheres
In situ forming implants
Drug-loaded implants
Controlled-release particles
Polymer matrices for peptides or proteins
Long-acting injectable suspensions
Local drug-delivery systems

The claims do not expressly require a drug or dosage form. A polymer manufacturer could therefore face direct infringement allegations even if it sells the material as an excipient rather than as a finished drug product.

A formulation containing conventional PLGA is not automatically within the patent. The formulation must contain the claimed polymer architecture and satisfy the relevant molecular and physical characteristics.

Does US 8,840,916 cover a drug listed in the Orange Book?

No Orange Book conclusion follows from the supplied claims alone. The claims are directed to a polymer, not to an active drug, drug formulation, method of treatment, or finished dosage form.

FDA Orange Book listing generally concerns patents associated with approved drug products, including qualifying drug-substance, drug-product, and method-of-use patents. An excipient or polymer patent may be commercially relevant to an approved product without being independently listed in the Orange Book. Orange Book listing must be assessed product by product against the approved application and FDA listing records.[2]

The patent should therefore be analyzed as a platform or drug-delivery patent rather than as a conventional drug patent.

When does US 8,840,916 lose exclusivity?

The supplied claim text does not establish the patent's earliest effective nonprovisional filing date, priority chain, patent-term-adjustment period, terminal disclaimer, reexamination history, or post-grant proceedings. Those records control the enforceable expiration date.

For a US utility patent, the ordinary term is generally 20 years from the earliest effective US nonprovisional filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and other statutory rules.[3] The grant date, September 23, 2014, is not itself the expiration date.

A reliable exclusivity timeline requires the complete continuity data and USPTO Patent Center record. The claims supplied do not establish that timeline.

What patent landscape surrounds the claimed polymer?

The relevant competitive patent landscape is divided into five technology groups.

Conventional PLGA composition patents

These patents generally cover:

Lactide/glycolide copolymer ratios
Molecular-weight ranges
End-group chemistry
Acid-terminated or ester-terminated PLGA
Polymer purity and residual monomer limits
Stereochemical composition
Degradation and release profiles

US 8,840,916 is potentially differentiated from conventional PLGA patents by its combination of terminal hydroxyl groups, an alkylene-linked architecture, limited titratable carboxylic acid functionality, and defined physical properties.

Drug-loaded microsphere patents

Microsphere patents commonly claim:

A specific active ingredient
Particle-size distribution
Drug loading
Encapsulation efficiency
Release profile
Solvent or emulsification process
Injectable administration

A competitor may avoid the polymer patent while remaining exposed to separate product or formulation patents covering the microsphere or drug product.

Long-acting injectable and implant patents

These patents may cover:

In situ depot formation
Biodegradable implants
Sustained release of peptides
Injectable polymer solutions or suspensions
Local tissue delivery
Specific excipient combinations

The polymer claim can operate independently of these formulation claims. A commercial product may require freedom to operate across several patent families.

Polymer manufacturing patents

Manufacturing claims may cover:

Ring-opening polymerization
Catalyst systems
Molecular-weight control
End-group capping
Removal of residual monomer
Control of polydispersity
Batch-to-batch reproducibility
Production of hydroxyl-terminated polymers

Manufacturing patents create a separate risk from composition claims. A supplier may avoid the composition claims but still infringe a process patent, or the supplier may practice the composition claims without infringing a process claim.

Alternative biodegradable polymers

Potential design-around materials include:

Polycaprolactone
Polylactide
Polyorthoesters
Polycarbonates
Polyhydroxyalkanoates
PEG-containing block copolymers
Acid-terminated or ester-terminated polymers outside the claimed architecture

The commercial tradeoff is that a design-around may change degradation rate, drug compatibility, release kinetics, injectability, or regulatory comparability.

What are the principal design-around strategies?

The most direct design-around options are:

Use a linker outside the claimed Ra definition.
Use a branched or substituted linker rather than a linear unsubstituted chain.
Use a polymer with substantial titratable carboxylic-acid functionality.
Use a molecular weight outside the effective claim 1 range.
Use a polymer that is liquid in neat form at ambient temperature.
Use lactide/glycolide ratios outside the dependent claim ranges.
Use a different polymer family, such as polycaprolactone or a polycarbonate.
Use an alternative terminal-group configuration.
Use a formulation containing a different polymer while preserving the same release profile through particle engineering or drug loading.

The strongest design-around depends on whether the performance requirement is driven by polymer chemistry or by the finished dosage form. Changing the linker or terminal chemistry may preserve biodegradation but alter release behavior and regulatory comparability.

What patent litigation and Paragraph IV risks exist?

Paragraph IV litigation is relevant only if an abbreviated new drug application, or ANDA, relies on a listed drug product for which this patent is listed in the Orange Book. A polymer-only patent is not automatically subject to Paragraph IV certification.

If the patent is not listed against the reference drug, an ANDA applicant generally would not make a Paragraph IV certification directed to this patent merely because the formulation uses a similar excipient. The patent could still support a separate infringement action against a manufacturer, supplier, or product applicant under ordinary patent law.

Potential litigation issues include:

Whether the accused polymer has the claimed Formula I/II architecture
Construction of "substantially no titratable carboxylic acid groups"
Meaning of "substantially insoluble"
Interpretation of "about" in molecular-weight and ratio ranges
Testing method for molecular weight and polydispersity
Testing method for inherent viscosity
Whether the neat polymer is solid at ambient temperature
Written-description support for the full genus
Enablement across the claimed molecular-weight and composition ranges
Obviousness over conventional PLGA, hydroxyl-terminated polymers, and linker-modified biodegradable polymers

The absence of a drug limitation increases potential reach across multiple products, but the analytical limitations may make infringement proof dependent on laboratory testing and expert testimony.

How strong is the patent estate?

The supplied claim set has moderate apparent commercial breadth but several litigation-sensitive limitations.

Strength factor	Assessment
Composition-of-matter coverage	Stronger than a method-only claim if the structure is adequately supported
Drug independence	Broadens potential product coverage
Formula dependence	Exact structural interpretation is critical
Molecular-weight limitation	Provides objective boundary but creates testing disputes
Acid-group limitation	Potentially valuable distinction from acid-terminated PLGA
Functional language	Creates ambiguity around insolubility and solid state
Dependent claims	Add useful fallback positions for ratios, linker length, PDI, and viscosity
Claim 4	Potential internal scope issue because it appears broader than claim 1
Design-around potential	Moderate, particularly through linker, end-group, or polymer-family changes
Regulatory leverage	Limited unless tied to an approved product and listed patent

The strongest claims are likely those combining a specific structural configuration with the six-carbon linker, 70/30 to 90/10 lactide/glycolide ratio, 15-45 kDa molecular weight, and narrower viscosity or polydispersity ranges. Those combinations may be easier to prove analytically but easier for a competitor to design around.

Key Takeaways

US 8,840,916 claims a defined PLG-containing biodegradable polymer, not a specific drug.
Claim 1 requires a particular formula, terminal hydroxyl groups, an alkylene linker, insolubility, minimal titratable carboxylic-acid functionality, a roughly 10-50 kDa molecular weight, and a solid neat form.
Claims 2, 3, 6, 8, 10, and 12 provide narrower commercial fallback positions.
Claim 4 appears numerically broader than claim 1 but remains subject to claim 1's inherited limitations.
The patent may affect injectable depots, microspheres, implants, and other controlled-release systems using the claimed polymer.
It is not, based on the supplied claims, a conventional Orange Book drug patent.
Paragraph IV exposure depends on whether the patent is listed against a specific approved drug product.
The main design-around routes are alternative linkers, terminal groups, acid functionality, molecular-weight ranges, or non-PLG polymer families.
The enforceable expiration date cannot be derived from the claim text alone.
Freedom-to-operate analysis requires separate review of composition, formulation, manufacturing, drug-specific, and method-of-use patent families.

Frequently Asked Questions

Is US 8,840,916 a PLGA patent?

It is a PLG-containing polymer patent. Its claims do not cover all PLGA or PLGA-based products because they require additional structural, terminal-group, molecular-weight, solubility, acid-functionality, and solid-state limitations.

Can a product infringe if it uses the polymer only as an excipient?

Yes. The claims are directed to the polymer itself. Therapeutic use is not required by the supplied claims. An excipient supplier or finished-product manufacturer could face exposure if the material satisfies the claimed limitations.

Does a six-carbon linker automatically create infringement?

No. A six-carbon linker is only one limitation in claim 8. The polymer must also satisfy the applicable inherited structural, terminal-group, PLG, molecular-weight, acid-functionality, solubility, and physical-state requirements.

Can changing the lactide/glycolide ratio avoid the patent?

It may avoid dependent claims 2 and 3, but it does not necessarily avoid claim 1. The broader claim 1 analysis depends on the formula and all non-ratio limitations.

Is a biosimilar analysis relevant to this patent?

Usually not directly. Biosimilar products are regulated under the biologics pathway, while this patent concerns a biodegradable polymer. The patent may still matter to a biologic depot or long-acting delivery system that uses the claimed polymer.

References

United States Patent No. 8,840,916, claims 1-12. U.S. Patent and Trademark Office, 2014.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
U.S. Patent and Trademark Office. (2024). Patent term adjustment and patent term extension. USPTO.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	259217	⤷ Start Trial
Austria	296088	⤷ Start Trial
Austria	458469	⤷ Start Trial
Australia	1331200	⤷ Start Trial
Australia	2001292931	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,840,916

Summary for Patent: 8,840,916